Madrigal Pharmaceuticals saw the highest growth of 1.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Madrigal Pharmaceuticals’s patent filings and grants. Buy the databook here.

Smarter leaders trust GlobalData

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Madrigal Pharmaceuticals has been focused on protecting inventions in United States(US) with four publications in Q2 2024

The United States(US) Patent Office dominates the patent filings and grants with nearly 50% filings and 50% grants. The United States(US), Australia(AU), Israel(IL), and South Korea(KR) patent Office are among the top ten patent offices where Madrigal Pharmaceuticals is filings its patents. Among the top granted patent authorities, Madrigal Pharmaceuticals has 50% of its grants in United States(US) and 50% in European Patent Office(EPO).

Gilead Sciences and Johnson & Johnson could be the strongest competitors for Madrigal Pharmaceuticals

Patents related to climate change and rare diseases lead Madrigal Pharmaceuticals's portfolio

Madrigal Pharmaceuticals has the highest number of patents in climate change followed by, rare diseases. For climate change, nearly 67% of patents were filed and 100% of patents were granted in Q2 2024.

Non-alcoholic steatohepatitis (nash) related patents lead Madrigal Pharmaceuticals portfolio followed by hypercholesterolemia, and manufacturing/industrial

Madrigal Pharmaceuticals has highest number of patents in non-alcoholic steatohepatitis (nash) followed by hypercholesterolemia, manufacturing/industrial, hyperlipidemia, and fatty liver disease. For non-alcoholic steatohepatitis (nash), nearly 11% of patents were filed and 9% of patents were granted in Q2 2024.

For comprehensive analysis of Madrigal Pharmaceuticals's filings and grants, buy the databook here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.

Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.